C3 helps protect lung cells from damage in pneumonia
C3 Mitigates Epithelial Injury in Pneumonia
['FUNDING_CAREER'] · WASHINGTON UNIVERSITY · NIH-10687247
This study is looking at how a protein called C3 might help protect lung cells from damage caused by pneumonia, with the hope of finding new treatments to make patients feel better.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10687247 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a protein called complement component C3 can help protect lung cells from injury caused by pneumonia. The principal investigator, a physician-scientist, is exploring the potential of C3 as a therapeutic agent to reduce the severity of pneumonia, which is a significant health concern. By studying the effects of C3 on cell survival and stress responses, the research aims to develop innovative treatments that could improve patient outcomes. The project involves collaboration with experts in various fields to ensure a comprehensive approach to tackling pneumonia-related challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pneumonia, particularly those experiencing severe symptoms or complications.
Not a fit: Patients with pneumonia who are not experiencing significant cell injury or who have mild cases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery and outcomes for patients suffering from pneumonia.
How similar studies have performed: Previous research has shown promise in using complement proteins for therapeutic purposes, indicating that this approach may lead to meaningful advancements in pneumonia treatment.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KULKARNI, HRISHIKESH SATISH — WASHINGTON UNIVERSITY
- Study coordinator: KULKARNI, HRISHIKESH SATISH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.